Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VAXX | US
0
0%
Healthcare
Biotechnology
01/01/1970
17/10/2024
0.00
0.02
0.06
0.00
Vaxxinity Inc. a biotechnology company focuses on developing product candidates for human use in the fields of neurology cardiovascular diseases and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301 an anti-tau product candidate for various neurodegenerative conditions including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus which is in phase 3 clinical trial. Vaxxinity Inc. was founded in 2014 and is headquartered in Merritt Island Florida.
View LessPrice Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
5154.9%1 month
145133.0%3 months
83215.1%6 months
65445.1%-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.06
Range1M
0.09
Range3M
0.37
Rel. volume
1.59
Price X volume
50.51
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.735 | 0 | -3.37% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 64.615 | 0 | -1.88% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2228 | 0 | -0.45% | n/a | |
VINC | VINC | Biotechnology | 0.3775 | 0 | -5.15% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.99 | 0 | 3.37% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.46 | 0 | -2.50% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 39.89 | 0 | -0.25% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.31 | 0 | -1.18% | n/a | |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.52 | 0 | -3.08% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 40.67 | 0 | -1.45% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 83,215.10 | 72.92 | Riskier |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | - | 3.78B | - |